查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612521

良性前列腺增生藥物市場：依產品、銷售管道- 全球預測 2025-2030

Benign Prostatic Hypertrophy Drugs Market by Product (5-alpha-reductase Inhibitors, Alpha Blockers, Phosphodiesterase-5 Inhibitors), Sales Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

良性前列腺增生治療市場2023年估值為51.5億美元，預計到2024年將達到55億美元，複合年成長率為6.97%，到2030年預計將達到82.6億美元。

良性攝護腺增生（BPH）治療市場的定義是旨在緩解男性前列腺非癌性增大引起的症狀的藥物，主要影響老年男性。由於人口老化、生活方式的改變以及改善尿流和減少相關症狀的健康意識的增強，前列腺增生症的盛行率不斷增加，因此對有效治療解決方案的需求凸顯。 BPH 治療方法包括 α阻斷劑、5-α 還原酶抑制劑、磷酸二酯酶 5 抑制劑和聯合治療，主要透過口服給藥。最終使用領域主要是醫院、診所和提供老年人護理的家庭護理機構。關鍵的成長要素包括前列腺相關疾病的盛行率上升、給藥技術的進步、醫療保健成本的上升以及更強力的報銷政策。然而，該市場面臨諸如替代療法的可用性、與良性前列腺增生藥物相關的副作用以及嚴格的監管核准等限制，這可能會阻礙成長動力。隨著新興經濟體的成長，由於醫療保健系統的改善、精準醫學研究的進步以及副作用更少的新配方的開發，擴張的機會正在出現。公司應瞄準個人化治療方法，並專注於教育醫療保健專業人員和患者了解新配方的好處和進步。必須注意已開發國家市場飽和、主要藥品專利到期等問題。數位健康解決方案和藥物開發策略聯盟的創新工作可以提供競爭優勢。市場競爭往往非常激烈，主要企業在進行策略性合併、收購和產品發布。因此，尋求成長的公司必須利用這些動態，探索市場利基，並確保合規性，以有效地利用不斷擴大的機會。

主要市場統計
基準年[2023] 51.5億美元
預計年份 [2024] 55億美元
預測年份 [2030] 82.6億美元
複合年成長率（%） 6.97%

市場動態：揭示快速發展的 BPH 藥物市場的關鍵市場洞察

供需的動態交互作用正在改變良性前列腺增生藥物的市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球良性攝護腺增生盛行率不斷上升
    • 支持性監理政策提高市場核准效率
  • 市場限制因素
    • 良性前列腺增生藥物的高成本和替代治療的可用性
  • 市場機會
    • 良性攝護腺增生藥物研發進展與創新
    • 加大新型給藥技術研發投入
  • 市場挑戰
    • 因安全問題而召回產品

波特五力：駕馭 BPH 藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對良性前列腺增生藥物市場的影響

外部宏觀環境因素在塑造良性前列腺增生藥物市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解良性攝護腺增生治療藥物市場的競爭狀況

對良性前列腺增生藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

良性前列腺增生藥物市場中的 FPNV 定位矩陣供應商績效評估

FPNV定位矩陣是評估良性前列腺增生藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃良性前列腺增生藥物市場的成功之路

對良性前列腺增生治療藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球良性攝護腺增生盛行率不斷上升
      • 支持性監理政策，提高市場核准效率
    • 抑制因素
      • BPH 藥物高成本且替代治療方法的可用性
    • 機會
      • BPH 藥物開發的進展與創新
      • 加大新型給藥技術研發投入
    • 任務
      • 因安全問題而召回產品
  • 市場區隔分析
    • 產品：加強研發開發下一代良性攝護腺增生治療藥物
    • 銷售管道：網路藥局業務成長加快
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章良性攝護腺增生藥物市場：依產品

  • 5α-還原酶抑制劑
  • α阻斷劑
    • 阿夫唑嗪
    • 多沙唑嗪
    • Tamsulosin
    • 特拉唑嗪
  • 磷酸二酯酶5抑制劑

第7章良性攝護腺增生藥物市場：依銷售管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專業藥房

第8章北美和南美良性前列腺增生藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區良性攝護腺增生治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東、非洲前列腺增生藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Zydus Lifesciences 新型前列腺治療膠囊獲得美國FDA核准
    • Bluewater Vaccines 策略收購 ENTADFI 擴大良性前列腺增生的治療選擇
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Advin Health Care
  • Alembic Ltd.
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • biolitec Holding GmbH & Co KG
  • Boston Scientific Corporation
  • CH Boehringer Sohn AG & Co. KG
  • Care Formulation Labs Pvt. ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Intas Pharmaceuticals Limited
  • Medifocus Inc.
  • Merck & Co., Inc.
  • Nymox Pharmaceutical Corporation
  • Onconetix, Inc.
  • Pfizer Inc.
  • Pharex Health Corporation
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • UNILAB, Inc.
  • Urologix, LLC
  • Zydus Lifesciences Limited
Product Code: MRR-CB04E056547E

The Benign Prostatic Hypertrophy Drugs Market was valued at USD 5.15 billion in 2023, expected to reach USD 5.50 billion in 2024, and is projected to grow at a CAGR of 6.97%, to USD 8.26 billion by 2030.

The market for Benign Prostatic Hypertrophy (BPH) drugs is typically defined by pharmaceutical products aimed at alleviating symptoms caused by the non-cancerous enlargement of the prostate gland in men, primarily affecting older adult males. The necessity for these drugs stems from the increasing prevalence of BPH due to demographic aging, lifestyle changes, and heightened health awareness, emphasizing the demand for effective therapeutic solutions that improve urinary flow and reduce associated symptoms. Applications of BPH drugs include alpha-blockers, 5-alpha-reductase inhibitors, phosphodiesterase-5 inhibitors, and combination therapies, primarily administered orally. The end-use segment predominantly covers hospitals, clinics, and home care settings that cater to geriatric care. Key growth influencers include the rising incidence of prostate-related disorders, technological advancements in drug delivery, increasing healthcare expenditure, and enhanced reimbursement policies. However, this market faces limitations such as the availability of alternative treatments, side effects associated with BPH drugs, and stringent regulatory approvals, which can impede growth dynamics. Opportunities for expansion are visible with the ongoing research in precision medicine and the development of novel formulations with lesser side effects, alongside growth in emerging economies due to improving healthcare systems. Companies should explore targeting personalized treatment approaches and focus on educating healthcare providers and patients about the benefits and advancements of newer drug formulations. Challenges like market saturation in developed regions and patent expirations of leading drugs require attention. Innovating around digital health solutions and engaging in strategic collaborations for drug development can offer competitive advantages. The market tends to be highly competitive with key players engaging in strategic mergers, acquisitions, and product launches. Thus, organizations aiming for growth should leverage these dynamics, seeking niche markets, and ensuring regulatory compliance to capitalize on expanding opportunities effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 5.15 billion
Estimated Year [2024] USD 5.50 billion
Forecast Year [2030] USD 8.26 billion
CAGR (%) 6.97%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Benign Prostatic Hypertrophy Drugs Market

The Benign Prostatic Hypertrophy Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing global prevalence of benign prostatic hypertrophy
    • Supportive regulatory policies enhancing market approval efficiency
  • Market Restraints
    • High cost of BPH drugs and availability of alternate treatments
  • Market Opportunities
    • Advancements and innovation in BPH drug development
    • Increased investment in R&D for novel drug delivery technologies
  • Market Challenges
    • Product recalls due to safety concerns

Porter's Five Forces: A Strategic Tool for Navigating the Benign Prostatic Hypertrophy Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Benign Prostatic Hypertrophy Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Benign Prostatic Hypertrophy Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Benign Prostatic Hypertrophy Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Benign Prostatic Hypertrophy Drugs Market

A detailed market share analysis in the Benign Prostatic Hypertrophy Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Benign Prostatic Hypertrophy Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Benign Prostatic Hypertrophy Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Benign Prostatic Hypertrophy Drugs Market

A strategic analysis of the Benign Prostatic Hypertrophy Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Benign Prostatic Hypertrophy Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Advin Health Care, Alembic Ltd., Asahi Kasei Corporation, Astellas Pharma Inc., biolitec Holding GmbH & Co KG, Boston Scientific Corporation, C.H. Boehringer Sohn AG & Co. KG, Care Formulation Labs Pvt. ltd., Eli Lilly and Company, GlaxoSmithKline PLC, Intas Pharmaceuticals Limited, Medifocus Inc., Merck & Co., Inc., Nymox Pharmaceutical Corporation, Onconetix, Inc., Pfizer Inc., Pharex Health Corporation, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UNILAB, Inc., Urologix, LLC, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Benign Prostatic Hypertrophy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across 5-alpha-reductase Inhibitors, Alpha Blockers, and Phosphodiesterase-5 Inhibitors. The Alpha Blockers is further studied across Alfuzosin, Doxazosin, Tamsulosin, and Terazosin.
  • Based on Sales Channel, market is studied across Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Specialty Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing global prevalence of benign prostatic hypertrophy
      • 5.1.1.2. Supportive regulatory policies enhancing market approval efficiency
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of BPH drugs and availability of alternate treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements and innovation in BPH drug development
      • 5.1.3.2. Increased investment in R&D for novel drug delivery technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Product recalls due to safety concerns
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing R&D towards development next generation benign prostatic hypertrophy drug
    • 5.2.2. Sales Channel: Rising business growth across online pharmacies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Benign Prostatic Hypertrophy Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. 5-alpha-reductase Inhibitors
  • 6.3. Alpha Blockers
    • 6.3.1. Alfuzosin
    • 6.3.2. Doxazosin
    • 6.3.3. Tamsulosin
    • 6.3.4. Terazosin
  • 6.4. Phosphodiesterase-5 Inhibitors

7. Benign Prostatic Hypertrophy Drugs Market, by Sales Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies
  • 7.5. Specialty Pharmacies

8. Americas Benign Prostatic Hypertrophy Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Benign Prostatic Hypertrophy Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Benign Prostatic Hypertrophy Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Zydus Lifesciences Secures USFDA Approval for Novel Prostate Treatment Capsules
    • 11.3.2. Strategic Acquisition of ENTADFI by Blue Water Vaccines Inc. for Enhancing Treatment Options for Benign Prostatic Hyperplasia
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Advin Health Care
  • 4. Alembic Ltd.
  • 5. Asahi Kasei Corporation
  • 6. Astellas Pharma Inc.
  • 7. biolitec Holding GmbH & Co KG
  • 8. Boston Scientific Corporation
  • 9. C.H. Boehringer Sohn AG & Co. KG
  • 10. Care Formulation Labs Pvt. ltd.
  • 11. Eli Lilly and Company
  • 12. GlaxoSmithKline PLC
  • 13. Intas Pharmaceuticals Limited
  • 14. Medifocus Inc.
  • 15. Merck & Co., Inc.
  • 16. Nymox Pharmaceutical Corporation
  • 17. Onconetix, Inc.
  • 18. Pfizer Inc.
  • 19. Pharex Health Corporation
  • 20. Sanofi S.A.
  • 21. Teva Pharmaceutical Industries Ltd.
  • 22. UNILAB, Inc.
  • 23. Urologix, LLC
  • 24. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023